Rapamycin (Sirolimus) Licensed by Pfizer

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Price Stock Quantity  
USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Rapamycin (Sirolimus) Chemical Structure

Rapamycin (Sirolimus) Chemical Structure
Molecular Weight: 914.18

Validation & Quality Control

Product Use Citation(55)

Customer Product Validation(12)

Quality Control & MSDS

Related Compound Libraries

mTOR Inhibitors with Unique Features

  • Pan mTOR inhibitor

    KU-0063794 mTORC1 and mTORC2, IC50=~10 nM.

  • FDA-approved mTOR Inhibitor

    Temsirolimus (CCI-779, NSC 683864) Approved by FDA for Renal Cell Carcinoma (RCC).

  • Newest mTOR Inhibitor

    XL388 Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

  • Classic mTOR Inhibitor

    BEZ235 (NVP-BEZ235, Dactolisib) Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Product Information

  • Compare mTOR Inhibitors
    Compare mTOR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets mTOR [1]
(HEK293 cells)
IC50 ~0.1 nM
In vitro Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29NFv5TFdEgXSxdH;4bYMhSXO|YYm=MmS0NVAhdk1?MXe3NkBpNEjZVWJFVVORMVPQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm=NIPNPWszPDlyMEi3Ny=>
HT-29NXLhS49ES3m2b4TvfIlkKEG|c3H5MUexNEBvVQ>?NGSxeZY4OiCqNXLCdpd[TE2VTx?=MYTQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl?MkGxNlQ6ODB6N{O=
HT-29NWK1SWUxS3m2b4TvfIlkKEG|c3H5M{fUPFExKG6PMnjDO|IhcA>?M{XlemROW09?NWTRVoRiWG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl?M2nVe|I1QTByOEez
PC3MlXST4lv[XOnIFHzd4F6MY[xNFAhdk1?M1uyZ|EhcA>?Mm\1SG1UVw>?NImwWpVRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=>NHn0VXMzOTl5OE[4Ny=>
PC3MlLoT4lv[XOnIFHzd4F6MoXINVAxKG6PM{Lj[|EhcA>?MkPsSG1UVw>?NUTmVWdbTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36=NGjicpgzOTl5OE[4Ny=>
PC3MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nGcFEvPSEQvF2=MUSxJIg>MlvBSG1UVw>?MlzWTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6PNGq1e|MzOTl5OE[4Ny=>
HEK293NGG0XIZHfW6ldHnvckBCe3OjeR?=M4jQWlExOCCwTR?=MWO4JIg>NH;UTGxFVVORNVHIfJlmUW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7NM4jCN|IyPTN7M{Cx
BT-20M3rKSmtqdmG|ZTDBd5NigQ>?Ml\KNlAh|ryPNE[xc5BFVVORNETJW2JFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?=NH;2fXozOTN3M{W1NS=>
U937NIDMXJpCdnSrYnHjeIVzcWGuIFHzd4F6NF7oT|c2OCEQvF2=MmniOFghcA>?MmPpSG1UVw>?NULnRZJWUW6mdXPld{BidnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3Rid3ns[EB1gXCnIFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhWGirbHHk[YxxcGmjLUGgTnI{OiCrbjDVPVM4KGOnbHzzMnTxNlEyPDJzME[=
U937NFzo[3VCdnSrYnHjeIVzcWGuIFHzd4F6NVTuWGNGPTBizszNNVLtXG1ZPDhiaB?=NFe1S|lFVVORM3;zZmRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhVUmSIIDyc5RmcW5vZHXmbYNq\W62IFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhUlJ|Mj2yJIlvKFV7M{egZ4VtdHN?NEL1XWkzOTF2MkGwOi=>
U937MnS0RY51cWKjY4TldolidCCDc4PhfS=>NVrpO4RXPTBizszNNV7kSXpPPDhiaB?=NUPteWh6TE2VTx?=NF7p[pRFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>?MkjsNlEyPDJzME[=
MCF-7NIrBdoJCfXSxcHjh[5khSXO|YYm=NWrudm9TOzBibl2=NFzrblc1KGh?NV:1ZphCTE2VTx?=MYrJcoR2[2W|IHH1eI9xcGGpeR?=MlGwNlAxOjhzM{S=
U87MGMmjkT4lv[XOnIFHzd4F6NWXPOlFSOSEQvF2=MVi2JIg>M2[0WWROW09?MVzQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>?NFv2TGkyQTh2OESwOC=>
U87MGMWTLbY5ie2ViQYPzZZk>NUjFfVRHOSEQvF2=NEm0Z2o3KGh?NEfseZVFVVORM2TXbHBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;uNYnRXnhoOTl6NEi0NFQ>
U87MGMmHST4lv[XOnIFHzd4F6Mn\BNUDPxE1?NUHNVm1{PiCqNW\pU3JKTE2VTx?=MUjEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?NH\IbFUyQTh2OESwOC=>
U87MGMmLnT4lv[XOnIFHzd4F6MXexJO69VQ>?M2fPNlYhcA>?MXHEUXNQM3X1UWRw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>?Mlr2NVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rhebMl\5RZV1d3CqYXf5JGF{e2G7NEnqWmoxNjJizszNM{jwcVI1KGh?MVfEUXNQNX3jRpFtUW6mdXPld{BifXSxcHjh[5k>MWSxPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3M2rt[2F2fG:yaHHnfUBCe3OjeR?=NWTSfHVuOC5{IN88US=>M4nJe|I1KGh?MXHEUXNQMkHtTY5lfWOnczDheZRweGijZ4m=NFP4c5cyQDN7MUm0PS=>
H4NHiwRWxHfW6ldHnvckBCe3OjeR?=M2HvZ|AvOiEQvF2=M37zZlI1KGh?M16xVmROW09?NH;KSGNKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{MorINVgxOjR3OES=
HeLaNV\hU3pJTnWwY4Tpc44hSXO|YYm=NFzyfoUyODBibl2=NH;Mcpc{PiCqMoKxSG1UVw>?NUfud2ZXUW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>?MmfjNVc2PjN|OEW=
HeLaMmjjSpVv[3Srb36gRZN{[Xl?M1ridFExOCCwTR?=MVyzOkBpMVLEUXNQMYfJcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44>MUCxO|U3OzN6NR?=
HeLaM3\tXWZ2dmO2aX;uJGF{e2G7MlX2NVAxKG6PM4XFSlM3KGh?MnTtSG1UVw>?NWXvV49YUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9vNF\KVGIyPzV4M{O4OS=>
SYFNUjkWWo3TnWwY4Tpc44hSXO|YYm=MoPLNVAxKG6PMlGzNlQhcA>?MlfDSG1UVw>?MontTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;uMkHnNVc2PjN|OEW=
SYFM4TwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLHdmwyODBibl2=Mn;5NlQhcA>?Mn7TSG1UVw>?NGnD[HlKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzzNX;kPIJDOTd3NkOzPFU>
HEK293TMUnBcpRqfmm{YXygRZN{[Xl?NXjSfWxpOSCwTR?=NVPjN5RNPCCmM2L1UGROW09?M4PRTmlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCUNTD3bZRpKEWFNUCgc4YhOC5zIH7NNI\Y[JAyPzR6NUWwNS=>
HEK293TM33SOGFvfGm4aYLhcEBCe3OjeR?=MX[xJI5OM{\nPFQh\A>?MULEUXNQMnrQTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2=M4fPUlE4PDh3NUCx
PBMCNHTuPI5HfW6ldHnvckBCe3OjeR?=NFnYTI4yKG6PM1jqTVE1KGR?NEjY[mNFVVORMkOwVoVlfWOnczDDR3I2KGSnboPpeJk>NVnw[JdoOTd2OEW1NFE>
PBMCNIG3bnZHfW6ldHnvckBCe3OjeR?=NHLVXYMyKG6PNGTmUXkyPCCmNFjjV4lFVVORNGfRUYlFd2W|IH7veEBi\m[nY4SgR3hEWjRiZHXud4l1gQ>?MlriNVc1QDV3MEG=
HEK293 cellsMlvVT4lv[XOnIFHzd4F6NF3le|U2OCCwTR?=MVS0OUBucW5?NV\GVZJ1TE2VTx?=M2O0ZmlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1?NVztUmJyOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-lucM1rybmZ2dmO2aX;uJGF{e2G7NXHnSpRmOTByIH7NM2DEXFQhcA>?NFT5RVJFVVORMWDJcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=>NV7GRo1rOTdzMkiyOlI>
Human mixed lymphocyteNXu2RWhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33KUFUhdk1?M4LMRWROW09?M4fuO2lEPTB;MT62JI5ONg>?NF[xWnoyPjF6NUi2OS=>
Lewis rat lymph node cellsM17uRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PUO|Uh|ryPMn\LSG1UVw>?NGS5RmxKSzVyPUKuOkDPxE1?MVixOlE5PTh4NR?=
cells from the thymus of normal BALB/c miceNUXaZZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH25eI0yOCCwTR?=NFe4Z|M4OiCqM1HI[2ROW09?NX;NOWtkUW6qaXLpeJMhdHmvcHjvdJJwdGmoZYLheIlwdiBqTFHGLUB4cXSqIFnDOVAhd2ZiMzDuUS=>NFO4dIIyODB{MUm0PC=>
MRK-nu-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlq2TWM2OD1yLki0OUBxVQ>?M3XvU3NCVkeHUh?=
OCUB-MM1rib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfVV2FKSzVyPUWuNlQheE1?NGXLZXZUSU6JRWK=
SF539NUPMeHU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTFzLk[gdG0>NXvGenZzW0GQR1XS
ES4MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml63TWM2OD1{MT61JJBOMVrTRW5ITVJ?
RL95-2M4XuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTyN|U3UUN3ME2xNFcheE1?M33HWnNCVkeHUh?=
LC-2-adMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XhS2lEPTB;NEKzJJBOMVHTRW5ITVJ?
DaudiMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPXTWM2OD12M{SgdG0>NFnFemlUSU6JRWK=
NTERA-S-cl-D1NX;zRZp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4TkfGlEPTB;NESzJJBONFniZYZUSU6JRWK=
OS-RC-2MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETld5RKSzVyPU[1NkBxVQ>?NYq4PZZVW0GQR1XS
VA-ES-BJNIDKNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;zZ5NlUUN3ME23NlMheE1?NHyyPWtUSU6JRWK=
GR-STMmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\sclFKUUN3ME24OFYheE1?NH7TcmZUSU6JRWK=
SW872M4n6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfRbXBKSzVyPUi0OkBxVQ>?M37RTnNCVkeHUh?=
NOS-1M1HUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXKT5RKSzVyPUi3NUBxVQ>?NGLvbmtUSU6JRWK=
MC116MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Ll[WlEPTB;OUi1JJBOM2jod3NCVkeHUh?=
NCI-H1355MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LwNmlEPTB;MT6wNUBvVQ>?M3TUeXNCVkeHUh?=
RPMI-8226M4ruTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHjTWM2OD1zLkG5JI5OM4GwUXNCVkeHUh?=
TE-15MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTFwM{[gcm0>NHrXfXRUSU6JRWK=
Ramos-2G6-4C10MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTyTWM2OD1zLkS2JI5ONGriNpNUSU6JRWK=
KU812M3nnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXlemZKSzVyPUKuNFEhdk1?MVPTRW5ITVJ?
EW-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYH3SIhuUUN3ME2yMlE4KG6PNVnxbHp{W0GQR1XS
KS-1M1zvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTWZo9KSzVyPUKuOFUhdk1?MofhV2FPT0WU
SK-LMS-1MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTJwNEmgcm0>NELPTGtUSU6JRWK=
TGBC1TKBMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\wOGlEPTB;Mj62PUBvVQ>?MmXqV2FPT0WU
TE-6MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\JdmNXUUN3ME2yMlc4KG6PMonSV2FPT0WU
ETK-1NIDIXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTJwOEKgcm0>NILsZ|VUSU6JRWK=
BE-13MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTJwOUmgcm0>MXTTRW5ITVJ?
A3-KAWNVPj[4J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\tNI1VUUN3ME2yMlk6KG6PM3S0dXNCVkeHUh?=
TE-10NGrhb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37IPGlEPTB;Mz6zJI5ONVe5U2NtW0GQR1XS
DOHH-2M{jZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTCTWM2OD1|LkO1JI5OMnvFV2FPT0WU
ES6MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnEeHhtUUN3ME2zMlQ{KG6PNFrSb25USU6JRWK=
OPM-2NH3GU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrDNZhKSzVyPUSuNVUhdk1?Mlj2V2FPT0WU
SH-4M2TtXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\PWGI5UUN3ME20MlM1KG6PNEPkSXZUSU6JRWK=
NB13MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHOze3dKSzVyPUSuN|Yhdk1?MVjTRW5ITVJ?
HUTU-80NGK5fXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7rdYNjUUN3ME20MlQzKG6PMmntV2FPT0WU
CCRF-CEMM{njZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTRwOUSgcm0>NGDSdWpUSU6JRWK=
TGBC24TKBMkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTVwNUGgcm0>NXvyfo1VW0GQR1XS
697MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXz6XHhwUUN3ME22MlI5KG6PMXXTRW5ITVJ?
J-RT3-T3-5NYTQTJRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTZwNE[gcm0>NUXmR|E2W0GQR1XS
KALS-1M2HZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTZwNU[gcm0>MYfTRW5ITVJ?
no-10NVX3NVVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLUTWM2OD15LkK5JI5ONELIUVhUSU6JRWK=
SK-NEP-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRThwN{mgcm0>MVHTRW5ITVJ?
L-540MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHqSYpKSzVyPUGwMlQzKG6PNV7rbGhWW0GQR1XS
JiyoyeP-2003NVLURXpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrHSW1PUUN3ME2xNE46PCCwTR?=M4nuZ3NCVkeHUh?=
HHNYXaVGUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTFzLkO5JI5OMk[4V2FPT0WU
SRNXrNRZR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHz4RVVKSzVyPUGxMlQ2KG6PMXvTRW5ITVJ?
QIMR-WILNGnHZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmWxTWM2OD1zMT64OUBvVQ>?MoHPV2FPT0WU
A4-FukNFPjRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTF|LkGyJI5OMVjTRW5ITVJ?
CESSMn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFH5b5FKSzVyPUGzMlE{KG6PMYfTRW5ITVJ?
KE-37Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2Hn[WlEPTB;MU[uNFchdk1?MU\TRW5ITVJ?
SK-UT-1M2iySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmW1TWM2OD1zNj64NUBvVQ>?NV\F[WRIW0GQR1XS
SIG-M5MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\FTWM2OD1zNz6yOUBvVQ>?M3nUfnNCVkeHUh?=
HTNXnHPYVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTF5Lk[gcm0>NWTYXFF3W0GQR1XS
DELMnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TNS2lEPTB;MUeuPVkhdk1?NHnFXo9USU6JRWK=
SK-PN-DWMnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknXTWM2OD1{MD6yN{BvVQ>?M1TQfHNCVkeHUh?=
RPMI-8402NF\KbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEO5NJBKSzVyPUKxMlc4KG6PNXq4c5J5W0GQR1XS
RPMI-6666MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnMRXcyUUN3ME2yOE41OiCwTR?=MWLTRW5ITVJ?
NCI-H720MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGqwd|NKSzVyPUK1MlQyKG6PMom5V2FPT0WU
EW-16NW[2SnZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoqyTWM2OD1{Nj64O{BvVQ>?NI\sd21USU6JRWK=
BL-70MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXDUVJKSzVyPUK4MlM5KG6PMVHTRW5ITVJ?
SF126MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTNyLkO4JI5ONE\Gbm1USU6JRWK=
BC-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nwOGlEPTB;M{GuNlYhdk1?M1rVfnNCVkeHUh?=
MHH-PREB-1Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LCb2lEPTB;M{KuOFQhdk1?M4HveXNCVkeHUh?=
A101DM2fJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1SxV2lEPTB;M{KuOlIhdk1?NVfsUWtoW0GQR1XS
NMC-G1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTVNZZyUUN3ME2zN{43PyCwTR?=NHLFXFRUSU6JRWK=
LB1047-RCCNVi1cm1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XtS2lEPTB;M{SuOlkhdk1?NHfiUHhUSU6JRWK=
EM-2M3flXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\pNXdKSzVyPUO4MlU{KG6PNGKzZ3hUSU6JRWK=
COLO-684NWLwWJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTN7Lkigcm0>MWHTRW5ITVJ?
BeckerMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPSTWM2OD12MT6wOUBvVQ>?M2m3U3NCVkeHUh?=
BL-41Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPZTW5KSzVyPUSzMlY3KG6PNVnKVGFnW0GQR1XS
MDA-MB-134-VIM3fvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXETWM2OD12ND6wNkBvVQ>?M2HHSHNCVkeHUh?=
L-363NV;JfVdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLJSoJKSzVyPUS0Mlc{KG6PNV3ZUmNGW0GQR1XS
ECC4NYnzTpBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXlTWM2OD12ND63PEBvVQ>?M3TxSXNCVkeHUh?=
A388Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\KTWZSUUN3ME20OE45OiCwTR?=M4WzPHNCVkeHUh?=
HELMnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HRdmlEPTB;NEmuO|khdk1?Mom4V2FPT0WU
RKOMlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\xcGlEPTB;NUCuNlkhdk1?MUHTRW5ITVJ?
KINGS-1NYq2XFRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjofnhKSzVyPUWxMlU2KG6PNVi4R3NIW0GQR1XS
EB-3MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zWSWlEPTB;NUKuOlchdk1?M3vhPHNCVkeHUh?=
ARH-77MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MornTWM2OD13Mj64JI5OMlPqV2FPT0WU
GCIYNXvVbo1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrMclFKSzVyPUWzMlQ3KG6PM2ftVXNCVkeHUh?=
NCI-H1304MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFH2ZpRKSzVyPUW3MlIzKG6PNWK2d|luW0GQR1XS
KARPAS-299NG\aNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTZzLkiyJI5OM2m2WXNCVkeHUh?=
IA-LMM3TyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTZ6LkGzJI5ONGr3WGtUSU6JRWK=
GI-1M4HoSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3WTWM2OD15MD6zPUBvVQ>?MoTZV2FPT0WU
TE-11M4i0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIG5SldKSzVyPUe3MlE4KG6PMXHTRW5ITVJ?
LS-411NM1TGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTITWM2OD15Nz61O{BvVQ>?MUnTRW5ITVJ?
no-11M{exRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTh|LkK0JI5OM1L2ZnNCVkeHUh?=
MV-4-11M3TuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4n1dmlEPTB;OEOuO|Mhdk1?NWDSTWt6W0GQR1XS
BV-173Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDwOmV5UUN3ME24N{46PyCwTR?=NFvCOGhUSU6JRWK=
CMKNYLDO4pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHaTWM2OD16ND6xOkBvVQ>?M4WxZXNCVkeHUh?=
LC4-1Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDGTWM2OD16Nj63NkBvVQ>?MlXaV2FPT0WU
COR-L279NELEfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTh5LkK1JI5OMkHQV2FPT0WU
NCI-H209NXTT[FRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\NTWM2OD16Nz60NUBvVQ>?NIjVTGJUSU6JRWK=
RajiM4XlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnT2TWM2OD16OT63NkBvVQ>?MUHTRW5ITVJ?
LB996-RCCMnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXPTWM2OD17Mz60N{BvVQ>?NVracGFKW0GQR1XS
NCI-H526MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTlTWM2OD17Mz61PUBvVQ>?MkLjV2FPT0WU
KGNNYjlfpVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnmyTWM2OD17Nj6yPUBvVQ>?NWPPdWRUW0GQR1XS
MOLT-4NXPU[W91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M170eWlEPTB;OU[uO|khdk1?NI\1dZVUSU6JRWK=
PF-382NF\2R3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXuPYlKSzVyPUm2Mlc6KG6PNELBO3FUSU6JRWK=
BC-3M{nyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fVOGlEPTB;OUmuNVghdk1?M4rRWnNCVkeHUh?=
KARPAS-422MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjQNZhKUUN3ME2xNFIvODlibl2=NIntb|VUSU6JRWK=
SBC-1NXXuTVE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInlfGFKSzVyPUGwO{44PSCwTR?=M17oc3NCVkeHUh?=
LC-1FNX\DS2l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTFyOD6wOUBvVQ>?MULTRW5ITVJ?
GB-1M1;6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PO[WlEPTB;MUC5MlAzKG6PMUTTRW5ITVJ?
SNB75MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XFUWlEPTB;MUG5MlY6KG6PMlziV2FPT0WU
BB65-RCCM1r0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHRT29KSzVyPUGxPU46OyCwTR?=M1n5Z3NCVkeHUh?=
NCI-N87MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3PeJpKSzVyPUGyNU46QCCwTR?=MUTTRW5ITVJ?
IST-MEL1Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTF{Mj6zPEBvVQ>?M3r6[3NCVkeHUh?=
HOP-62MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;IS2lEPTB;MUK2Mlg6KG6PNUnSOm81W0GQR1XS
ACNM1XTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTlTWM2OD1zNE[uO|Uhdk1?NX;UVWJEW0GQR1XS
DMS-114NWjaSZdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTnSYd4UUN3ME2xOVAvPjdibl2=MmLFV2FPT0WU
MLMAMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7Ed|NKSzVyPUG1PU45QCCwTR?=NWH1ZVFHW0GQR1XS
HT-144NVjIU3g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTF4NT60N{BvVQ>?M37WOnNCVkeHUh?=
C2BBe1NEPqU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Kx[2lEPTB;MU[3Mlc3KG6PMX3TRW5ITVJ?
L-428NVfLcGRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvqS|RKSzVyPUG3O{44KG6PM1\JZ3NCVkeHUh?=
DU-4475NIXQdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTF6Nz62PEBvVQ>?NGC0cGlUSU6JRWK=
CP67-MELMn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPsSWlLUUN3ME2xPVkvOzhibl2=NXKx[4Y6W0GQR1XS
MEG-01MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4L3cmlEPTB;MkCxMlk3KG6PMYrTRW5ITVJ?
IST-SL2MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTJyOD62N{BvVQ>?MkXuV2FPT0WU
ES8NX[zd2JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYT6TZgzUUN3ME2yNlUvQTRibl2=MUjTRW5ITVJ?
COLO-800M33mPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\FN2NYUUN3ME2yN|UvOjhibl2=NXvWWo11W0GQR1XS
MFH-inoNGTtc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTJ|NT64OEBvVQ>?MVLTRW5ITVJ?
OVCAR-4MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4r1RmlEPTB;MkO3MlI1KG6PNV7DUmtbW0GQR1XS
PSN1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWW5U2djUUN3ME2yOFIvPzFibl2=NEX0RZJUSU6JRWK=
EW-12MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHuzblVKSzVyPUK0N{4yKG6PMW\TRW5ITVJ?
HCC1599MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7JWIxKSzVyPUK2NU41PyCwTR?=NWnXR3pRW0GQR1XS
SJSA-1NWq0ToQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfwTZAyUUN3ME2yO|EvPDZibl2=Ml;5V2FPT0WU
ST486MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTJ7Nj6xOEBvVQ>?MXPTRW5ITVJ?
NOMO-1NXLROFFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTNyMD6yNUBvVQ>?MV7TRW5ITVJ?
MN-60NH[4TWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzlSYlKSzVyPUOwOU4{OiCwTR?=MmD3V2FPT0WU
HCC1187M371d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7obIZ7UUN3ME2zNFcvOjVibl2=NFzJb2dUSU6JRWK=
SW982M4DzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmmxTWM2OD1|MUSuO|Uhdk1?M{PmU3NCVkeHUh?=
LB647-SCLCMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPHWWV{UUN3ME2zNlgvPzFibl2=NYjITllXW0GQR1XS
HC-1NX7DbW5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\RSFZKSzVyPUOzOU42KG6PMnyzV2FPT0WU
EHEBNHy0Tm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTN|Nz61NkBvVQ>?NGfoTWlUSU6JRWK=
TURM2H6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmm0TWM2OD1|NkOuPVUhdk1?MlTXV2FPT0WU
LU-139M{jYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTN5OD6wNkBvVQ>?MUXTRW5ITVJ?
NB1NVfROG03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPnU2xYUUN3ME2zPFQvPDVibl2=NF3yVGNUSU6JRWK=
BB30-HNCM3;veWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\sTWM2OD1|OEiuN|Ihdk1?MkX4V2FPT0WU
HAL-01M17CNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fRRmlEPTB;M{i5MlI3KG6PMke2V2FPT0WU
K5M{\GeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\aTWM2OD12MUGuN|chdk1?NFXOSXVUSU6JRWK=
MZ2-MELNIHzXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnETWM2OD12MUOuOlQhdk1?NIf1N29USU6JRWK=
RXF393M1f3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;yW2lEPTB;NEG2MlQ2KG6PMXLTRW5ITVJ?
NCI-H1648NWTKeYw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHYdZFKSzVyPUSxO{42OyCwTR?=NHu5RWxUSU6JRWK=
TE-12MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1THWGlEPTB;NEO0MlI3KG6PM2\sV3NCVkeHUh?=
EoL-1-NHrwSHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M363cWlEPTB;NEO3Mlk5KG6PMUjTRW5ITVJ?
JARMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvkWmRjUUN3ME20N|gvPjJibl2=M37PNXNCVkeHUh?=
DSH1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DLWGlEPTB;NEW4MlkyKG6PMWPTRW5ITVJ?
NCI-H187MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorFTWM2OD12NkKuPFEhdk1?M4C5enNCVkeHUh?=
HCE-4NUXCOGdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3e0NWlEPTB;NEe3MlY3KG6PMoPQV2FPT0WU
8-MG-BANFLHT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTV6MT61NkBvVQ>?NUW5bpptW0GQR1XS
KLENFXCflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITQRlBKSzVyPUW4OU4zKG6PMVXTRW5ITVJ?
KNS-42NGj6WZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXuTWM2OD13OE[uPFEhdk1?M4C1S3NCVkeHUh?=
MSTO-211HMkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTZyOT63OEBvVQ>?MofvV2FPT0WU
GDM-1NULiNXFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTZzND6wPUBvVQ>?M37Hc3NCVkeHUh?=
TE-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLOTWM2OD14NE[uNVIhdk1?MX7TRW5ITVJ?
BT-474MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrOOpZnUUN3ME22OFcvODZibl2=Ml7mV2FPT0WU
KARPAS-45NUfD[2NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jId2lEPTB;NkS3MlYhdk1?M4i4WXNCVkeHUh?=
MOLT-16M3XJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NES3c5RKSzVyPU[0O{46OyCwTR?=NY\Wco0yW0GQR1XS
KURAMOCHIMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHrSYFKSzVyPU[1O{42OSCwTR?=M3vmenNCVkeHUh?=
K-562MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\STWM2OD14NkmuOVEhdk1?NYPad4JvW0GQR1XS
EKVXMo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;DVHVbUUN3ME22O|IvPzFibl2=MUXTRW5ITVJ?
GAKM{XtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\sT|RKSzVyPU[3OU4{KG6PMkj6V2FPT0WU
NCI-SNU-5NYftTHFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jaNmlEPTB;NkmwMlAyKG6PNFTCWFhUSU6JRWK=
NCI-H2126Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTd{Nj64O{BvVQ>?NUDJdXB3W0GQR1XS
CTV-1M{PNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlH3TWM2OD15NESuPUBvVQ>?M37RbHNCVkeHUh?=
SW962M4T6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjPVJVKSzVyPUe0PE41PCCwTR?=M{jjWXNCVkeHUh?=
MONO-MAC-6M3vidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\5TWM2OD15NU[uPVMhdk1?M{nMUXNCVkeHUh?=
NCI-H748MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTd3OD65PUBvVQ>?MXXTRW5ITVJ?
NCI-H524M2LtfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHOwTVFKSzVyPUe4NE44OyCwTR?=MlLFV2FPT0WU
LS-123NWT1e3R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPGN5VOUUN3ME23PVUvPjlibl2=M2XYbXNCVkeHUh?=
NB7NWLydlFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PiU2lEPTB;OEG0MlE1KG6PMX3TRW5ITVJ?
LS-1034MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWP5XmUzUUN3ME24NlgvQThibl2=NUK1bINRW0GQR1XS
TE-5NXi3fZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7jTWM2OD16OEOuOVYhdk1?MnLvV2FPT0WU
A704MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTh7OT6xOUBvVQ>?NVLnWWR4W0GQR1XS
TK10NHHZUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfpRm5KSzVyPUmxOk4xOyCwTR?=MnvsV2FPT0WU
NCI-H345MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnEcXFKSzVyPUm0N{4zOiCwTR?=M3XXOXNCVkeHUh?=
CGTH-W-1NGez[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1ywcGlEPTB;OUS4MlE{KG6PMm\uV2FPT0WU
NCI-H510AMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWWwW5U4UUN3ME25PFUvOTJibl2=MXrTRW5ITVJ?
NCI-H1963Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFSzV4dKSzVyPUGuNFMzQTJizszNMmXGV2FPT0WU
SCC-3NXvVcWM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXRT4hKSzVyPUGuNFM1OTRizszNMWnTRW5ITVJ?
EW-11NF3rU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTtXpJKSzVyPUGuNFg4PDNizszNNGfvTWlUSU6JRWK=
CPC-NMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXxTWM2OD1zLkC4PEDPxE1?MnG3V2FPT0WU
NCI-H1417NXiwV|hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;zVmlEPTB;MT6xNlI3KM7:TR?=NHHxPGJUSU6JRWK=
DG-75NWjqV2NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTnRWVKSzVyPUGuNVYzQDVizszNMUXTRW5ITVJ?
HD-MY-ZMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLib3NjUUN3ME2xMlE3PDF4IN88US=>M2i2V3NCVkeHUh?=
ATN-1NUfLPZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYK3U2ZCUUN3ME2xMlI3OjB7IN88US=>MXLTRW5ITVJ?
KM-H2NWT5cINkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1f2PWlEPTB;MT6yOlQxQCEQvF2=NX3McnZjW0GQR1XS
NCI-H2081MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnyNXlKSzVyPUGuNlY3OzdizszNNYDXRnZ3W0GQR1XS
HL-60NE\TRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3P2TmlEPTB;MT6yOlk2QSEQvF2=Ml3vV2FPT0WU
DBMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVz4cYdIUUN3ME2xMlI4OjR{IN88US=>NGf1WYRUSU6JRWK=
NCI-H1522M{Kwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3zXI1rUUN3ME2xMlI5QDh5IN88US=>MlXrV2FPT0WU
AM-38NEXJSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHUTWM2OD1zLkOwO|Ih|ryPMYfTRW5ITVJ?
NCI-H446NX7nb404T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DBcmlEPTB;MT6zNlEzOSEQvF2=MlyyV2FPT0WU
SU-DHL-1NVrWVWNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDRTWM2OD1zLkOyPFAyKM7:TR?=NYrOVZlMW0GQR1XS
NH-12NGD0bGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTVTWpKSzVyPUGuN|Y{PzRizszNNXXwNJhTW0GQR1XS
DMS-79MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnf0TWM2OD1zLkO2PFY3KM7:TR?=NUnYTIhpW0GQR1XS
NCI-H716NFXoSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTFwM{i5PFYh|ryPM{XM[3NCVkeHUh?=
ML-2NH3ITodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHF[mRNUUN3ME2xMlQyPTJ7IN88US=>NVH5bJBIW0GQR1XS
NB10NUXORVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLBTWM2OD1zLkS2OlMzKM7:TR?=NEG3Z49USU6JRWK=
ONS-76M3K3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHyZ25iUUN3ME2xMlU{PTZ7IN88US=>NHjLfXVUSU6JRWK=
LOUCYNWPJUJl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\GTFhKSzVyPUGuOVQ3PTdizszNM{HqUHNCVkeHUh?=
SCLC-21HM1LhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHjTWM2OD1zLkW4OVgzKM7:TR?=Mk\zV2FPT0WU
TGWNFfTdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTFwNkO5O|Uh|ryPMoXaV2FPT0WU
LXF-289MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nuOGlEPTB;MT63N|I3QCEQvF2=MWfTRW5ITVJ?
BB49-HNCMlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHrXGFKSzVyPUGuO|M2QDZizszNMlLJV2FPT0WU
NCI-H747NE\LWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTFwN{WzOFYh|ryPM4PPVXNCVkeHUh?=
LU-165MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTFwOES5PFYh|ryPM4DNc3NCVkeHUh?=
OMC-1NHjXZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTFwOUWwOlYh|ryPMYjTRW5ITVJ?
RCC10RGBMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXwN2RsUUN3ME2xMlk2QDF5IN88US=>NHy3THdUSU6JRWK=
SW684MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnYT28yUUN3ME2xMlk3ODl7IN88US=>NHHjTWdUSU6JRWK=
TE-8M2rZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjDc3RKUUN3ME2yMlA2PTV7IN88US=>NWjn[WVwW0GQR1XS
SK-N-DZMoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1T5PWlEPTB;Mj6xN|I4PCEQvF2=M{DhbnNCVkeHUh?=
EVSA-TMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLOTWM2OD1{LkG3N|E2KM7:TR?=MorsV2FPT0WU
KASUMI-1NFPyO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LCT2lEPTB;Mj6xPFgyPSEQvF2=Mn:2V2FPT0WU
NKM-1NFH0U4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnKU2tKSzVyPUKuNlU1PzJizszNMYrTRW5ITVJ?
CAL-148MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInqeVNKSzVyPUKuN|M3OTRizszNM4mzVHNCVkeHUh?=
NCI-H64NYTOV|NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTJwM{SyN|Ih|ryPNUf5VoJ3W0GQR1XS
KNS-81-FDMmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XJbGlEPTB;Mj6zOlYzKM7:TR?=NFXuTFhUSU6JRWK=
KM12NHn5SWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTJwNEC4N|kh|ryPNIr0fXVUSU6JRWK=
SW954MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTJwNEe3O|kh|ryPM17C[3NCVkeHUh?=
NCI-H1395NWr0Uo03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfHNJVKSzVyPUKuOVI3PDVizszNM2DuVnNCVkeHUh?=
DJM-1NW\D[pV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVewcXM4UUN3ME2yMlYxPjNizszNNX\IendiW0GQR1XS
COLO-668NYjvbYVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoS4TWM2OD1{LkiyOlk2KM7:TR?=NXPSS2U3W0GQR1XS
NCI-H1436MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTJwOEW2NVUh|ryPMV;TRW5ITVJ?
LB2241-RCCM4iz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TRT2lEPTB;Mj64Olg{QSEQvF2=NG\2W2ZUSU6JRWK=
GT3TKBNXfJdZhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LRRWlEPTB;Mj64PVA2PSEQvF2=MYrTRW5ITVJ?
COLO-824M3jTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17YTmlEPTB;Mj64PVc3QCEQvF2=NXvaUoZwW0GQR1XS
ES1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PM[2lEPTB;Mj64PVg4QSEQvF2=NGr4cGVUSU6JRWK=
LB771-HNCNFHzOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTJwOUC5OFYh|ryPMWTTRW5ITVJ?
GI-ME-NMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;kZWlEPTB;Mz6wNFkxPCEQvF2=MkfZV2FPT0WU
NALM-6M{jMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTNwMEC5N|Mh|ryPMoPZV2FPT0WU
LU-134-ANGjReWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XDb2lEPTB;Mz6wOVQzPSEQvF2=NHjHO2RUSU6JRWK=
DMS-153NVyycnRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;vSlVKSzVyPUOuNFU5OjRizszNNHrK[4VUSU6JRWK=
MZ1-PCNEHNe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELzTZFKSzVyPUOuNFkxPzhizszNNEPsRoZUSU6JRWK=
NCI-H1155Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELnTIJKSzVyPUOuNVE3OSEQvF2=MlLjV2FPT0WU
CAS-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPiTWM2OD1|LkGzO|A4KM7:TR?=MV\TRW5ITVJ?
D-502MGNWjUXIRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHVTWM2OD1|LkG0N|kh|ryPNF3GfphUSU6JRWK=
NCI-H2141MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULFWYttUUN3ME2zMlE4PDV{IN88US=>M3PD[3NCVkeHUh?=
NB6MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTNwMUiyOVkh|ryPMYPTRW5ITVJ?
NCCITNGn0XphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorKTWM2OD1|LkKxPFA6KM7:TR?=MnHiV2FPT0WU
NB69MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTNwM{G4PVEh|ryPMX7TRW5ITVJ?
JVM-2Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHriO41KSzVyPUOuN|Y1OzNizszNNID1PZhUSU6JRWK=
K052NGW0XYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDPTWM2OD1|LkO3PVY5KM7:TR?=MnHMV2FPT0WU
HCC2157MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHu0[IVKSzVyPUOuOVMzOjhizszNNGHv[XBUSU6JRWK=
KMOE-2M3;QVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTNwNUSyOFIh|ryPNVnVeFdtW0GQR1XS
SF268NUK5[|NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rCdmlEPTB;Mz63NVU2PCEQvF2=MYTTRW5ITVJ?
CHP-126MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jtXGlEPTB;Mz63OlQ2QCEQvF2=NIfjTFJUSU6JRWK=
CP66-MELNUG4cZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HRbWlEPTB;Mz63PVA6PCEQvF2=NFnF[XNUSU6JRWK=
NCI-H69MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HkemlEPTB;ND6wNVk{PiEQvF2=MlH3V2FPT0WU
A253MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPHTmlKSzVyPUSuNFIyODFizszNMUPTRW5ITVJ?
NB14NU\ncZcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIiyT21KSzVyPUSuNVA1PzlizszNNWD2SmhbW0GQR1XS
NCI-H1694NYGxO4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3:2PWlEPTB;ND6xN|EyOiEQvF2=NVv6cZJ2W0GQR1XS
NCI-H2196MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXyTWM2OD12LkG3NVY6KM7:TR?=MortV2FPT0WU
TE-9MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfsWpZKSzVyPUSuNVc2QDJizszNM4W3[HNCVkeHUh?=
D-283MEDMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXXc|ZKSzVyPUSuNVg5PCEQvF2=NV7JOWdNW0GQR1XS
OCI-AML2MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLlNpJlUUN3ME20MlE6PDh7IN88US=>MV7TRW5ITVJ?
D-263MGNIfhS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTRwMkK5OlEh|ryPNVHPeldrW0GQR1XS
MPP-89NVS2PFFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPOTWM2OD12LkK3N|A1KM7:TR?=MkTXV2FPT0WU
LAMA-84MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUK1ZVdlUUN3ME20MlMxPDJzIN88US=>MYDTRW5ITVJ?
LB373-MEL-DM2XNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLwV|d5UUN3ME20MlM3Pzh7IN88US=>NX\XSVJXW0GQR1XS
UACC-257MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XmRWlEPTB;ND6zPVU{PCEQvF2=M2DLPXNCVkeHUh?=
MC-CARMl7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTRwNEO5PUDPxE1?NVnaS4xTW0GQR1XS
COLO-320-HSRNIfOWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3Pa[WlEPTB;ND60OFQzPyEQvF2=M4PkSXNCVkeHUh?=
P30-OHKMlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTRwNk[1PFEh|ryPNWPBR5FCW0GQR1XS
UACC-812NXTYbZYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fCUGlEPTB;ND62PVE3OSEQvF2=MX\TRW5ITVJ?
CTB-1M1nMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;sT4FrUUN3ME20MlcyPTV3IN88US=>MmrFV2FPT0WU
ALL-PONXH3OYRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvxWlRKSzVyPUSuPFQxPzdizszNNITmSpNUSU6JRWK=
SK-MEL-2MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XZVmlEPTB;ND64Olk2PSEQvF2=MW\TRW5ITVJ?
TC-YIKMkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfaTWM2OD12Lkm3PVQzKM7:TR?=Mk\ZV2FPT0WU
NCI-H1882NGi1eHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoG0TWM2OD13LkCyNFAyKM7:TR?=MnHYV2FPT0WU
MHH-CALL-2MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTVwMEWwOFIh|ryPMl6wV2FPT0WU
U-87-MGNFWzUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTVwMEm0OlYh|ryPNHLP[WpUSU6JRWK=
NCI-H1092MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37nVWlEPTB;NT6yOlU2PSEQvF2=NVTJeWlYW0GQR1XS
TE-441-TMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzGTmNDUUN3ME21MlI4QDJizszNMYHTRW5ITVJ?
SK-MEL-1NGfOV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjJTWM2OD13LkK5NFQ1KM7:TR?=M33idXNCVkeHUh?=
EW-22NGLNcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmL1TWM2OD13LkK5OFY3KM7:TR?=MkSzV2FPT0WU
MZ7-melMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTVwNEC2PVEh|ryPM1\KWXNCVkeHUh?=
LP-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTVwNEGyPVEh|ryPMkfuV2FPT0WU
NCI-SNU-16NH;pOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTVwNkSwO|Qh|ryPMmTuV2FPT0WU
LU-65M4KxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTVwN{[zO|Mh|ryPM3LZN3NCVkeHUh?=
CW-2M3rLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1W2NmlEPTB;NT64OVk2QSEQvF2=NInkdotUSU6JRWK=
WSU-NHLMnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;rTWM2OD13Lkm1NVc1KM7:TR?=NHr3b4ZUSU6JRWK=
IST-MES1MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHUTWM2OD13Lkm1OFQ{KM7:TR?=MXHTRW5ITVJ?
U-266MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DyV2lEPTB;NT65PFIxOiEQvF2=NWH1ZmQ3W0GQR1XS
TALL-1NYjrR|VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTZwMUS2PFgh|ryPMXzTRW5ITVJ?
Calu-6MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHzTIxDUUN3ME22MlE2OzF4IN88US=>NF7NeFdUSU6JRWK=
MMAC-SFNYX6[JBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTZwMUi1OVYh|ryPNVXO[HNMW0GQR1XS
NCI-H82NFPSOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTZwMkC0PFkh|ryPNFPQPFZUSU6JRWK=
RS4-11NFvLcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXuTWM2OD14LkK1PFk4KM7:TR?=NF;ZNohUSU6JRWK=
SNU-C2BMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlToTWM2OD14LkSwPVY6KM7:TR?=NVew[XprW0GQR1XS
BOKUNFvSO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfSTWM2OD14LkS3OVk4KM7:TR?=MoHRV2FPT0WU
C8166M{j5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEP0Um9KSzVyPU[uOVU6OTJizszNNWT4OotRW0GQR1XS
D-247MGMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHhW|lKSzVyPUeuNFQ{PDdizszNNFLPcJZUSU6JRWK=
EW-18NWPOWpBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3X1V2lEPTB;Nz6wO|I6OiEQvF2=NInUZYNUSU6JRWK=
KG-1NGi0fZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTdwNkK3N|gh|ryPMUTTRW5ITVJ?
REHNH;zT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3scoRDUUN3ME23MlY5OTB7IN88US=>MX;TRW5ITVJ?
U-698-MMoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPoTWM2OD15Lki0N|E2KM7:TR?=MX7TRW5ITVJ?
KP-N-RT-BM-1MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1q5T2lEPTB;Nz65N|AzQSEQvF2=MX3TRW5ITVJ?
MS-1NX\LUpN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTdwOU[wOFEh|ryPM4D3b3NCVkeHUh?=
SNU-C1NXLIO2Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTdwOUixPVIh|ryPNH7WV|RUSU6JRWK=
SK-MM-2NH\vV|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nDbWlEPTB;OD6yOlA3PSEQvF2=MVXTRW5ITVJ?
LAN-6MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmKyTWM2OD16LkOwNFAyKM7:TR?=MnfMV2FPT0WU
NEC8MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRThwM{C2PVEh|ryPMorwV2FPT0WU
NCI-H1770MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRThwM{iwNFIh|ryPNWXmPWNrW0GQR1XS
D-336MGMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3j5bGlEPTB;OD60NFEyPiEQvF2=M4PoWHNCVkeHUh?=
COLO-829MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1S5cmlEPTB;OD60PFg4QSEQvF2=Mo\qV2FPT0WU
LS-513M3fx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRThwNUm1PVkh|ryPMXTTRW5ITVJ?
YTMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrVUIZ[UUN3ME24MlYzPDJ5IN88US=>Mk\SV2FPT0WU
EW-24NVjWPIR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfSc2trUUN3ME24Mlc3PTRizszNMoDCV2FPT0WU
IST-SL1MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{K1[WlEPTB;OD64OlU1OyEQvF2=MYPTRW5ITVJ?
CA46MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRThwOUWwPVgh|ryPNVPh[JlZW0GQR1XS
NCI-H1838MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrPRlZCUUN3ME24Mlk5PjB{IN88US=>NVXoNndWW0GQR1XS
NCI-H719M33qNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTlwMkWyO|kh|ryPMXPTRW5ITVJ?
HCE-TMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorETWM2OD17LkOwPFUyKM7:TR?=MYnTRW5ITVJ?
A498MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljPTWM2OD17LkO2NVI1KM7:TR?=NHfF[odUSU6JRWK=
LB831-BLCMl\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTlwN{[1NlEh|ryPM3LuWXNCVkeHUh?=
SKM-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnWTWM2OD17Lki1PVY{KM7:TR?=M2PnZ3NCVkeHUh?=
THP-1NU[yVmUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTlwOU[5NVgh|ryPMV;TRW5ITVJ?
SHP-77NWDaWY5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TmcWlEPTB;MUCuOFA4KM7:TR?=M1LGT3NCVkeHUh?=
EW-3MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTFyLk[yPFkh|ryPNX;0NGxOW0GQR1XS
KY821NF7TUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrrTWM2OD1zMD63OlMh|ryPM{PhVXNCVkeHUh?=
NCI-SNU-1MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTFzLkCyNVch|ryPMXvTRW5ITVJ?
HCC2218MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUH5dHR3UUN3ME2xNU4{QTh4IN88US=>MUjTRW5ITVJ?
IM-9NEK4e4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TTdGlEPTB;MUGuOVExPiEQvF2=NY\ib5pGW0GQR1XS
NCI-H889MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmj0TWM2OD1zMT61N|E{KM7:TR?=NEjnWmhUSU6JRWK=
HDLM-2M2\qSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3R[5B2UUN3ME2xNk41OTV7IN88US=>MmX2V2FPT0WU
LB2518-MELM4jFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofPTWM2OD1zMj62PFE2KM7:TR?=MVXTRW5ITVJ?
NCI-H23NVzMNnFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTF|LkK0NlUh|ryPMXPTRW5ITVJ?
NB17M4njT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fERWlEPTB;MUOuOFU4QSEQvF2=MmXmV2FPT0WU
NCI-H322MM1ziU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXBeoVxUUN3ME2xOE41ODZ6IN88US=>MX3TRW5ITVJ?
SUP-T1MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\3flhKSzVyPUG0MlQyOyEQvF2=MnnkV2FPT0WU
ES3M4SzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XUbGlEPTB;MUWuNFcxOyEQvF2=NXK2eW1SW0GQR1XS
ES5MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLGTWM2OD1zNT6wO|g4KM7:TR?=MnXwV2FPT0WU
NCI-H1650MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfmZ2NvUUN3ME2xOU41QTd7IN88US=>NED3ZWVUSU6JRWK=
NCI-H226MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXKUI1KSzVyPUG1Mlg4PjhizszNNYHsPIdnW0GQR1XS
COR-L88MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfRTJpKSzVyPUG2MlMyPCEQvF2=NVXHUYpCW0GQR1XS
SCC-15NFi3RWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoToTWM2OD1zNj6zPFY6KM7:TR?=MUPTRW5ITVJ?
GOTOMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPjU5ZKSzVyPUG2MlQ4QTNizszNNFftTY5USU6JRWK=
SIMANVr2dmxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfGeJZXUUN3ME2xOk41QDB{IN88US=>NF;pXXFUSU6JRWK=
NCI-H1299MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4C3O2lEPTB;MUeuNVU6OSEQvF2=Mo\VV2FPT0WU
NCI-H1581MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTF5LkSyNVkh|ryPNWLme3hIW0GQR1XS
MHH-NB-11NUniZ3I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrsW3N[UUN3ME2xO{46Pjh|IN88US=>MV\TRW5ITVJ?
MFM-223M4jL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7TbZFKSzVyPUG4MlA2OzhizszNNX7lZ5VEW0GQR1XS
ES7NELkTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTF6LkW0N|Eh|ryPMUnTRW5ITVJ?
JVM-3M{nDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrGfmdKSzVyPUG4MlcyPyEQvF2=NEW1O5BUSU6JRWK=
RLM1P1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfYb3ZKSzVyPUKwMlM5QCEQvF2=M3Oxc3NCVkeHUh?=
EC-GI-10M{TMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrNT4dKSzVyPUKxMlIxPDFizszNM1WyW3NCVkeHUh?=
LNCaP-Clone-FGCM1juW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzaZYpKSzVyPUKxMlY4PjhizszNM2WxZ3NCVkeHUh?=
IMR-5M4jISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnjTWM2OD1{MT64OFk1KM7:TR?=NYLoNnVuW0GQR1XS
KP-N-YSNYrUZVFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTJzLki3OUDPxE1?MmW1V2FPT0WU
Mo-TMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVf0[owxUUN3ME2yNk4zOTh3IN88US=>NVTHd3F6W0GQR1XS
NCI-H128MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XCZmlEPTB;MkOuOVg2OyEQvF2=NX7HRY9[W0GQR1XS
RH-1NH7rN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojoTWM2OD1{Mz63PFY3KM7:TR?=MUfTRW5ITVJ?
NCI-H2171MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;ITWM2OD1{ND6yOFg2KM7:TR?=MYnTRW5ITVJ?
RPMI-8866MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnqN5JxUUN3ME2yOk44PDJizszNNWXoPYpvW0GQR1XS
SK-N-FINFnGW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rKWGlEPTB;MkeuN|gyOSEQvF2=M1vhOHNCVkeHUh?=
LOXIMVIM1\JOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PFdGlEPTB;MkeuPFA2OSEQvF2=M3PncnNCVkeHUh?=
P31-FUJNFWwcJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjCTWM2OD1|MT61N|c1KM7:TR?=Mkf0V2FPT0WU
KMS-12-PEM1nlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLLTWM2OD12OT61N|AzKM7:TR?=M4L5enNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

Cell Assay:

[3]

Cell lines U87-MG, T98G, and U373-MG
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

Animal Study:

[7]

Animal Models Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
Formulation Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
Dosages ~4 mg/kg/day
Administration Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Edwards SR, et al. J Biol Chem, 2007, 282(18), 13395-13401.

[2] Barbet NC, et al. Mol Biol Cell, 1996, 7(1), 25-42.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-01-10)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02240407 Not yet recruiting Pompe Disease University of Florida October 2016 Phase 1
NCT02567435 Not yet recruiting Alveolar Rhabdomyosarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Rhabdomyosarcoma|Sclerosing Rhabdomyosarcoma|Spindle  ...more Alveolar Rhabdomyosarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Rhabdomyosarcoma|Sclerosing Rhabdomyosarcoma|Spindle Cell Rhabdomyosarcoma|Untreated Childhood Rhabdomyosarcoma National Cancer Institute (NCI) June 2016 Phase 3
NCT02646319 Not yet recruiting Adult Solid Neoplasm|Advanced Malignant Neoplasm|Cervical Squamous Cell Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent  ...more Adult Solid Neoplasm|Advanced Malignant Neoplasm|Cervical Squamous Cell Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Malignant Neoplasm|Recurrent Ovarian Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Uterine Corpus Carcinoma|Sarcoma|Stage III Bladder Cancer|Stage III Renal Cell Cancer|Stage IIIA Breast Cancer|Stage IIIA Cervical Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Uterine Corpus Cancer|Stage IIIB Breast Cancer|Stage IIIB Cervical Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC Breast Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Uterine Corpus Cancer|Stage IIIC1 Uterine Corpus Cancer|Stage IIIC2 Uterine Corpus Cancer|Stage IV Breast Cancer|Stage IV Ovarian Cancer|Stage IV Renal Cell Cancer|Stage IVA Bladder Cancer|Stage IVA Cervical Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Bladder Cancer|Stage IVB Cervical Cancer|Stage IVB Uterine Corpus Cancer Mayo Clinic|National Cancer Institute (NCI) May 2016 Phase 2
NCT02596828 Not yet recruiting Pineoblastoma University of Regensburg April 2016 Phase 2
NCT02456857 Not yet recruiting Breast Cancer M.D. Anderson Cancer Center March 2016 Phase 2

view more

Chemical Information

Download Rapamycin (Sirolimus) SDF
Molecular Weight (MW) 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms AY 22989,NSC-2260804
Solubility (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC/0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

Customer Product Validation (12)


Click to enlarge
Rating
Source Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

Click to enlarge
Rating
Source 2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Product Use Citation (55)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related mTOR Products

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin (Compound C, BML-275)

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • INK 128 (MLN0128)

    INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • KU-0063794

    KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Recently Viewed Items

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus) price | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) solubility dmso | Rapamycin (Sirolimus) purchase | Rapamycin (Sirolimus) manufacturer | Rapamycin (Sirolimus) research buy | Rapamycin (Sirolimus) order | Rapamycin (Sirolimus) mouse | Rapamycin (Sirolimus) chemical structure | Rapamycin (Sirolimus) mw | Rapamycin (Sirolimus) molecular weight | Rapamycin (Sirolimus) datasheet | Rapamycin (Sirolimus) supplier | Rapamycin (Sirolimus) in vitro | Rapamycin (Sirolimus) cell line | Rapamycin (Sirolimus) concentration | Rapamycin (Sirolimus) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us